In millions, except per share items | Jun-30-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
Cash flows from operating activities: | | | | | | | | |
Net loss | | -19.4 | -20.9 | -18.3 | -19.4 | -19.1 | -17.2 | -16.7 |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |
Depreciation of property and equipment | | 0.0 | 0.2 | 0.4 | 0.5 | 0.7 | 0.6 | 0.7 |
Redeemable warrants valuation adjustment | | | | 0.0 | | | | |
Amortization of patent, trademark rights | | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Changes in ROU assets | | -0.7 | -0.7 | -0.7 | 0.0 | 0.0 | 0.0 | 0.0 |
Equity-based compensation | | 1.0 | 1.0 | 1.1 | 1.3 | 1.6 | 1.8 | 1.7 |
Change in assets and liabilities: | | | | | | | | |
Funds Receivable from New Jersey net operating loss | | 0.0 | | 0.0 | | -0.6 | | 0.8 |
Prepaid expenses and other current assets and other non-current assets | | -0.2 | 1.1 | 1.5 | 1.6 | 1.6 | 0.0 | 0.0 |
Lease liability | | 0.7 | 0.7 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 |
Other Assets | | -0.1 | | -0.1 | | | | |
Accounts payable | | 0.2 | 0.6 | 0.3 | 0.2 | -0.2 | 0.2 | 0.2 |
Accrued expenses | | 0.4 | 1.4 | 0.1 | -0.2 | 0.0 | 0.0 | -0.2 |
Net cash used in operating activities | | -16.1 | -15.8 | -14.3 | -13.7 | -14.0 | -11.1 | -10.6 |
|
Cash flows from investing activities: | | | | | | | | |
Proceeds from sale of marketable securities | | 10.1 | 30.5 | 29.4 | 20.7 | 22.3 | 0.8 | 1.6 |
Purchase of marketable securities | | -2.7 | -22.6 | -21.7 | -22.1 | -22.5 | -3.1 | -13.1 |
Proceeds from sale of property and equipment | | 3.9 | 0.3 | | | | | 0.2 |
Net cash (used in) provided by investing activities | | 11.0 | 8.0 | 7.4 | -1.5 | -0.6 | -1.2 | -10.4 |
|
Cash flows from financing activities: | | | | | | | | |
Proceeds from sale of stock, net of issuance costs | | | 0.2 | 0.2 | | 13.0 | 16.1 | |
Net cash provided by financing activities | | | 0.2 | 0.2 | | 8.2 | 11.1 | 28.2 |
Net (decrease) increase in cash and cash equivalents | | | | 2.4 | | | | |
|
Supplemental disclosures of non-cash investing and financing cash flow information: | | | | | | | | |
Unrealized gain (loss) on marketable securities | | | | | | | | |
Conversion of Series B preferred | | | | | | | | |